Pharmacokinetic and Pharmacodynamic (PK-PD) Studies of Cardiovascular Drugs (U01)
The summary for the Pharmacokinetic and Pharmacodynamic (PK-PD) Studies of Cardiovascular Drugs (U01) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the Food Drug Administration, which is the U.S. government agency offering this grant.
Pharmacokinetic and Pharmacodynamic (PK-PD) Studies of Cardiovascular Drugs (U01): Background: Metoprolol is a selective β1 receptor blocker used in treatment of several cardiovascular diseases, especially hypertension. Metoprolol is metabolized primarily by the cytochrome P450 isoform CYP2D6, which is subject to a genetic polymorphism. It has been formulated in different salt forms including tartrate, fumarate, and succinate salts, as well as different dosage forms such as immediate release and, extended release products. Different metoprolol drug products showed different pH-dependent drug release characteristics which seem to be consistent with the observed PK profile differences. The US FDA currently recommends single dose bioequivalence studies in healthy subjects to establish the bioequivalence of generic metoprolol products with their corresponding reference listed drug (RLD) based on 90% confidence interval of Cmax and AUC within 80.00-125.00%. The same bioequivalence criteria apply to any post approval changes of brand products which require in-vivo bioequivalence studies. Therapeutic inefficacy and adverse events have been reported by physicians and patients switching from brand to generic metoprolol extended release products. The FDA continues to monitor the FDA Adverse Event Reporting System (FAERS) for reports relating to currently marketed metoprolol products. However, based on current data available to the agency, it is difficult to draw definitive conclusions about the cause of the concern. Therefore, PK/PD studies in patient population are needed to help address the potential bioequivalence and therapeutic equivalence issues with metoprolol products. Objectives: The objectives of this project are to conduct a prospective PK/PD study in hypertensive patients to link the PK profiles to the time-course of PD activity of metoprolol, therefore, to identify the key product attributes and patient factors that may impact the therapeutic equivalence of metoprolol products. The specific objectives of the study were to: 1) Evaluate the PK-PD relationship; 2) Evaluate the effect of treatment (before and after switching metoprolol products) on the PK-PD relationship; 3) Evaluate the effect of pH variation in the population and rate of delivery on the PK-PD relationship; 4) Evaluate the effect of CYP2D6 phenotype on the PK-PD relationship; Detailed Description: Additional details regarding the study objectives are listed below: A prospective, randomized crossover trial design is suggested, i.e., switching over to a different metoprolol product at the same dose level as the prior one. The study should use a combination of products having different shapes of PK profiles. Simultaneous collections of PK and PD samples (before and after switch) at steady state are recommended to link PK profiles to PD effect. The selection of appropriate PD endpoint(s) has to be well justified. The study should enroll CYP2D6 extensive and poor metabolizers to assess the CYP2D6 phenotype impact on the PK profiles and PD activity of metoprolol extended release tablets. The study should evaluate the pH variations of the population and its impact on the PK profiles and PD effect of metoprolol extended release tablets. The focus of the first year is to develop a study protocol for FDA Research in Human Subject Committee (RIHSC) and investigator Institution Research Board (IRB) approval, product blinding, quality testing, bioanalytical method validation, and patient enrollment.
Federal Grant Title: | Pharmacokinetic and Pharmacodynamic (PK-PD) Studies of Cardiovascular Drugs (U01) |
Federal Agency Name: | Food Drug Administration |
Grant Categories: | Health Science and Technology |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-FD-14-024 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.103 |
CFDA Descriptions: | Food and Drug Administration_Research |
Current Application Deadline: | Jun 2, 2014 |
Original Application Deadline: | Jun 2, 2014 |
Posted Date: | Apr 18, 2014 |
Creation Date: | Apr 18, 2014 |
Archive Date: | Jul 2, 2014 |
Total Program Funding: | $3,000,000 |
Maximum Federal Grant Award: | $1,000,000 |
Minimum Federal Grant Award: | $750,000 |
Expected Number of Awards: | 1 |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- City or township governments
Others (see text field entitled "Additional Information on Eligibility" for clarification)
For profit organizations other than small businesses
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Small businesses
Public and State controlled institutions of higher education
State governments
Special district governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Independent school districts
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
County governments
Native American tribal governments (Federally recognized) - Additional Information on Eligibility
- Foreign Recipients
- Link to Full Grant Announcement
- Copy of published RFA
- Grant Announcement Contact
- Gladys Melendez-Bohler
Grants Management Officer/Specialist
Phone 240-402-7565
FDA Office
Food & Drug Administration 301-443-5869 - Similar Government Grants
- • Convener and Organizer of Activities and Engagements Related to Processes, Surveillance, a...
- • Development and Maintenance of the Animal Food Regulatory Program Standards (U19) Clinical...
- • Use of Digital Health Technologies in Clinical Investigations to Support Drug and Biologic...
- • Cooperative Agreement to Support the World Trade Organization's (WTO) Standards and Trade ...
- • Cooperative Agreement for Long Term Data Collection on Antimicrobial Use in Animals (U01) ...
- • Support for Small Scientific Conference Grant Program
- • Cooperative Agreement to Support the World Health Organization (WHO) International Program...
- • Clinical Studies of Safety and Effectiveness of Orphan Products
- More Grants from the Food Drug Administration
- • NARMS Cooperative Agreement Program to Enhance and Strengthen Antibiotic Resistance Survei...
- • Cooperative Agreement to Support Shellfish Safety Assistance Project (U01)
- • Native American Tribes Outreach, Education, and Training to Enhance Food Safety and FSMA C...
- • Local Food Producer Outreach, Education, and Training to Enhance Food Safety and FDA Food ...
- • National Training, Education, Extension, Outreach, and Technical Assistance Competitive Gr...